

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

Chin Med Sci J  
June 1999

Vol. 14, No. 2  
P. 102-106

## CHINESE MEDICAL SCIENCES JOURNAL

### THE RELATIONSHIP BETWEEN EXPRESSIONS OF N-myc AND c-myc ONCOGENES IN NEUROBLASTOMA; AN *IN SITU* HYBRIDIZATION AND IMMUNOCYTOCHEMICAL STUDY\*

Zhe Xiaoning\* (折晓宁), Chen Jie\*<sup>△</sup> (陈杰), Liu Tonghua\* (刘彤华),  
Zhang Lei\* (张雷), Li Peijuan\*\* (李佩娟) and Wang Detian\* (王德田)

\*Department of Pathology, Peking Union Medical College Hospital, National Laboratory  
of Medical Molecular Biology, CAMS & PUMC, Beijing 100730

\*\*Department of Pathology, Beijing Children's Hospital, Beijing 100045

**Key words** neuroblastoma; N-myc; c-myc

N-myc gene amplification is the most characteristic feature of neuroblastoma. c-myc oncogene, another member of myc gene family, plays an important role in cell proliferation and differentiation. Both of them may contribute to tumorigenesis of neuroblastoma. In this study we use the *in situ* hybridization and immunocytochemical methods to test the frequencies of N-myc and c-myc expressions in 20 cases of human neuroblastoma at mRNA and protein levels. The positive rates of the expression of N-myc are 90% and 100% detected by *in situ* hybridization and immunocytochemical methods respectively. The positive rates of c-myc are 80% and 85% respectively. Sixty percent of the 20 specimens tested by *in situ* hybridization and 55% by immunocytochemistry show an inverse relationship between the expressions of these two oncogenes and this may indicate that there are different gene expression controlling mechanisms in different cases.

#### INTRODUCTION

Neuroblastoma originates from the sympathoadrenal lineage of the neural crest and it is the most common extra-cranial tumor of childhood(1). Despite distinct improvement in treatment of this tumor, children with advanced-stage disease still have a poor prognosis. Recent cytogenetic and molecular biological studies have

Received for publication Feb. 16, 1998.

<sup>△</sup>Corresponding author.

\* This investigation was supported by Grants from National Committee of Education and Grants for Outstanding Young Scientist.

V  
lect  
am  
teri  
wir  
me:  
tan  
can  
my  
rob  
tio:  
pre:  
mR  
the  
cnc  
  
emb  
tain  
men  
wer  
L-ly  
  
der:  
trar  
was  
pro:  
Hun  
lishe  
for  
  
NA  
Dr.  
by:  
DN:  
Man  
  
parn  
eth:  
(10:  
fixe:  
in P  
ing  
0.5:  
shea  
com:  
citra  
cuba  
slide:  
2X5  
XS  
mam

led to a better understanding of this tumor. N-myc gene amplification and over-expression are the most characteristic feature of neuroblastoma, which closely correlate with clinical outcome (2). c-myc oncogene is another member of the myc gene family, which plays an important role in cell proliferation and differentiation, and it can also induce cell apoptosis (3). Both N-myc and c-myc oncogenes may contribute to tumorigenesis of neuroblastoma. In this study, we use both *in situ* hybridization and immunocytochemical methods to detect the expressions of these two oncogenes in neuroblastoma at mRNA and protein levels, and try to find some clues of the relationship between the expressions of these two oncogenes.

### MATERIALS AND METHODS

**Tissue preparation.** The formalin-fixed, paraffin-embedded surgically resected neuroblastoma tissues obtained from 20 patients were collected from the Department of Pathology, Beijing Children's Hospital. Tissues were cut into 5  $\mu$ m thick sections and mounted on poly-L-lysine-coated slides.

**Cell lines.** The cell line IMR-32/NGFR, which was derived from human neuroblastoma cell line IMR-32 by transfecting with recombinant NGFR retroviral vector, was used as positive control for N-myc, since it had been proved to have over-expression of N-myc oncogene (4). Human pancreatic carcinoma cell line PC-2 was established in our department and served as positive control for c-myc, since it had a high expression of c-myc (5).

**Probes.** Plasmids containing N-myc and c-myc cDNA fragments (1.0 kb both) were kindly provided by Dr. A. H. Ross from USA. The probes were labeled by the random primed labeling method using a DIG DNA Labeling and Detection Kit (Boehringer Mannheim).

**In situ hybridization (6).** Tissue sections were deparaffinized in xylene, rehydrated through a graded ethanol, rinsed in PBS and treated with proteinase K (100  $\mu$ g/ml, 30 min at 37°C). The slides were then re-fixed in 4% paraformaldehyde solution for 5 min, rinsed in PBS, and covered with hybridization solution containing 1 ng/ $\mu$ l heat-denatured probe, 50% formamide, 0.5% SDS (sodium dodecyl sulphate), 100  $\mu$ g/ml sheared salmon sperm DNA, 6  $\times$  SSC (1  $\times$  SSC was composed of 150 mmol/L NaCl and 15 mmol/L sodium citrate) and 5  $\times$  Denhardt's solution. The slides were incubated overnight at 42°C. After hybridization, the slides were stringently washed as follows: 0.1% SDS, 2  $\times$  SSC twice for 10 min at 42°C; 50% formamide, 2  $\times$  SSC for 10 min at room temperature, twice; 50% formamide, 0.5  $\times$  SSC for 10 min at room temperature,

twice; 0.2  $\times$  SSC for 5 min at room temperature; 0.1  $\times$  SSC for 2 min at room temperature. The slides were then visualized using anti-digoxigenin-alkaline phosphatase conjugate and NBT (nitro-blue tetrazolium)/BCIP (5-bromo-4-chloro-3-indolyl phosphate) substrates according to the instruction of the kit.

**Antibodies.** Rabbit anti-human N-myc polyclonal antibody corresponding to amino acid 445-463 mapping at the carboxy terminus of human N-myc oncoprotein was purchased from Santa Cruz Inc., USA. Mouse anti-human c-myc monoclonal antibody corresponding to amino acid 408-420 of human c-myc oncoprotein was purchased from Novo Inc., USA.

**Immunocytochemistry.** Tissue sections were deparaffinized and rehydrated, then covered with endogenous peroxidase blocking solution for 10 min, rinsed in PBS, 10% non-immune serum for 20 min, rinsed in PBS, then the primary antibody was applied (the two antibodies were all diluted to 1:50), and incubated overnight at 4°C. After rinsing in PBS thoroughly, the biotinylated second antibody was added and left for 10 min. Then the slides were rinsed in PBS, streptavidin-peroxidase conjugate solution was applied to the slides and left for 10 min, rinsed in PBS, then visualized with a solution containing 0.05% 3,3'-diaminobenzidine and 0.01%  $H_2O_2$ , sections can also be counterstained with hematoxylin.

### RESULTS

**General clinical and histopathological features.** The mean age of these 20 patients is 2.2 years, ranging from 1 month to 5 years. The ratio of male and female is 1.86:1 (13 males and 7 females). The sites of these 20 tumors are as follows: 8 in retroperitoneal region, 6 in adrenal glands, 2 in mediastinum, 1 in anterior region of sacrum and 3 from lymph node metastasis. Histologically, most tumors are composed of small round cells, with deep stained nuclei and scant cytoplasm, arranging in solid sheets, and hyperplastic blood vessels are prominent between the sheets. Among these tumors, Hower-Wright rosettes are found in 8 cases, and neurofibrile network is prominent in 5 cases. In 3 cases, the foci of ganglioneuroma are found. In another one, the tumor is composed mainly of ganglioneuroma and only small foci of neuroblastoma is found. The latter four patients are older than 4 years.

**Expressions of N-myc and c-myc oncogenes.** Results of the expressions of N-myc and c-myc oncogenes detected by the two methods are shown in Table 1.

The positive signals detected by *in situ* hybridization are shown as violet or blue deposits located mainly

Table 1. Expressions of N-myc and c-myc oncogenes in neuroblastoma by *in situ* hybridization (ISH) and immunocytochemical (ICC) method

Case	N-myc		c-myc	
	ISH	ICC	ISH	ICC
1	++	+	+	-
2	+++	++	±	±
3	-	=	+++	++
4	±	=	+++	++
5	+	-	+	±
6	-	=	+++	+++
7	+	+	-	-
8	++	+	+	+
9	+++	++	+++	-+
10	+++	++	-	±
11	±	±	+++	++
12	++	+	-	+
13	++	+	++	+
14	+++	-+	++	+
15	++	+++	±	++
16	++	++	±	-
17	±	+	+	++
18	+	+	-	-
19	+++	++	++	+
20	++	+	+	++

in nuclei and perinuclear regions due to scanty cytoplasm of neuroblastoma cells (Fig 1); the positive signals of immunocytochemical detection are brown deposits located mainly in nuclei. According to the proportion of positive cells in the tumors, the detecting results are divided as follows: ± (positive cells fewer than 25%), + (25%~50%), ++ (50%~75%), +++ (more than 75%). The expression rates of N-myc and c-myc are 90% and 80% respectively as detected by *in situ* hy-




Fig 1. The positive signals of N-myc oncogene by *in situ* hybridization method are violet-blue deposits locating mainly in nuclei and perinuclear regions.

bridization method. The immunocytochemical method shows the similar results, i. e. expression rates of N-myc and c-myc are 100% and 85% respectively. There is no significant difference between the positive rates obtained by the two methods.

The relationship between the expressions of the two oncogenes. It was found by *in situ* hybridization method that 8 out of 20 cases of neuroblastoma which have relatively strong N-myc expressions (++~+++) have



Fig 2. Neuroblastoma of case 2 shows strong N-myc expression (A) but very weak c-myc expression (B). (*in situ* hybridization)

no or only weak c-myc expressions (+~-) (Fig 2A, B); whereas 4 cases with strong c-myc expressions (++~+++) have no or only very weak N-myc expressions (Fig 3A, B). Immunocytochemical method also gives the similar results. Only 20% of the 20 cases detected by *in situ* hybridization and 10% detected by immunocytochemical method show both strong expressions (++~+++) of the two oncogenes. This inverse relationship between the expressions of the two oncogenes is shown in Table 2 and Table 3.

## DISCUSSION

Several genetic features which are the characteristics of neuroblastoma have been identified, these include



Fig 3. Neuroblastoma of case 4 shows strong c-myc expression (A) but very weak N-myc expression (B). (in situ hybridization)

Table 2. Comparison between the strength of expressions of the two oncogenes as detected by in situ hybridization method

		c-myc		Total
		++~+++	-~+	
N-myc	++~+++	4	8	12
	-~+	4	4	8
Total		8	12	20

Table 3. Comparison between the strength of expressions of the two oncogenes as detected by immunocytochemical method

		c-myc		Total
		++~+++	-~+	
N-myc	++~+++	2	5	7
	-~+	6	7	13
Total		8	12	20

hyperdiploidy, deletion of 1 p, and amplification of N-myc oncogene (7-9). The amplification of N-myc could be the most important feature in neuroblastoma since the tumors with amplified N-myc usually are associated with rapid tumor progression and a poor outcome. A general correlation between N-myc copy number and

expression has been shown, but it has been shown that a substantial number of tumors without N-myc amplification also overexpress this gene (10-12). In this study, it was found that there were quite high rates of expression of N-myc oncogene in these cases, i. e. 90% by *in situ* hybridization method and 100% by immunocytochemical method. This may indicate that over-expression of N-myc may play an important role other than gene amplification, since only about 25% to 30% of the children with neuroblastoma have N-myc amplification in their tumors. Meanwhile it was also found there was a high expression rate of c-myc oncogene in these cases by *in situ* hybridization and immunocytochemical methods. Along with the result of N-myc expression, we believe that the two oncogenes may contribute to the tumorigenesis of neuroblastoma. Although N-myc and c-myc can co-express in the same tumor, it is interesting to note that 60% of the 20 cases show an inverse relationship between the expressions of the two oncogenes when we compare the strength of expression of them. The cases with strong expression of N-myc usually have very weak expression of c-myc, and *vice versa*. Studies on neuroblastoma-derived cell lines also provide similar results (13, 14), but the mechanism is poorly understood so far, it may represent the important event in gene regulation process controlling cell growth and differentiation. Further studies are needed to clarify the relationship between the expressions of these two oncogenes.

## REFERENCES

1. Kushner BH and Cheung NK. Neuroblastoma. *Pediatr Ann*, 1988, 17:269-84.
2. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastoma. *N Engl J Med*, 1985, 313:1111-16.
3. Packham G and Cleveland JL. c-myc and apoptosis. *Biochim Biophys Acta*, 1995, 1242:11-28.
4. Chen Jie, Liu TH and Ross AH. Expression of recombinant NGF receptor in human neuroblastoma cell line without NGF receptor. *Basic Med Sci Clin*, 1991, 11:26-31.
5. Li DC, Liu TH, Cui QC, et al. Expression of c-myc and c-Ki-ras oncogene in human pancreatic carcinoma. *Chin J Oncol*, 1992, 14:30-32.
6. Polak JM and McGee JO. *In situ hybridization: Principles and practice*. Oxford: Oxford University Press, 1990, 59-70.
7. Look AT, Hayes FA, Nitschke R, et al. Cellular DNA content as predictor of response to chemotherapy in infants with unresectable neuroblastoma. *N Engl J Med*, 1984, 311:231-35.
8. Brodeur GM and Fong C. Molecular biology and genetics of human neuroblastoma. *Cancer Genet Cytogenet*, 1989, 41:153-74.
9. Brodeur GM and Seeger RC. Gene amplification in human neuroblastoma: basic mechanisms and clinical implications.

- Cancer Genet Cytogenet, 1986, 19:101-11.
10. Bartram CR and Berthold F. Amplification and expression of the N-myc gene in neuroblastoma. Eur J Pediatr, 1987, 146:162-65.
  11. Nisen PD, Washer PG, Rich MA, et al. N-myc oncogene RNA expression in neuroblastoma. J Natl Cancer Inst, 1988, 80:1633-37.
  12. Seeger RC, Wada R, Brodeur GM, et al. Expression of N-myc by neuroblastomas with one or multiple copies of the oncogene. Progr Clin Biol Res, 1988, 271:41-49.
  13. Breit S and Schwab M. Suppression of c-myc by high expression of N-myc in human neuroblastoma cells. J Neurosci Res, 1989, 24:21-28.
  14. Chen J, Liu TH and Ross AH. Down-regulation of c-myc oncogene during NGF-induced differentiation of neuroblastoma cell lines. Chin Med Sci J, 1994, 9:152-56.

## Preparation of Recombinant $\alpha 2$ Antigen of *M. Leprae* in *E. Coli* and the Application for Sero-diagnosis of Leprosy

Yin Yueping (尹跃平), Suzuki Yasuhiko\* (铃木定彦), Makino Masanao\*\* (牧野正直),  
Wu Qinxue (吴勤学) and Hou Wei (侯伟)

Institute of Dermatology, CAMS & PUMC,  
National Center for STD and Leprosy Control, Nanjing 210042

Leprosy is remain a major public health problem in some developing countries. Because *M. leprae* cannot be grown in vitro, purified protein of native antigen is unavailable. An antigen is a prominent target of the humoral and cellular immune responses against mycobacteria and may be useful to the development of novel vaccines and immunodiagnostic reagents. For the development of novel immunodiagnostic reagents, the recombinant  $\alpha 2$  antigen of *M. leprae* was prepared using the molecular biologic tools and the recombinant DNA expression technology.

Screening of the *M. leprae* expression library was performed by the plaque hybridization technique. Nucleotide sequences were determined by dideoxy termination method using A. L. F. florescent auto DNA sequencer. pMALc-RI was used as an expression vector. The antibody titer of anti-recombinant *M. leprae*  $\alpha 2$  antigen in leprosy was examined by enzyme-linked immunosorbent assay (ELISA).

The results are: (1) By screening 10 000 plaques of *M. leprae* genomic library, two clones of  $\alpha 2$  gene could be obtained. One of the two clones carrying the  $\alpha 2$  gene was selected and digested by appropriate restriction enzymes, then were cloned into pUC18 or 19 sequencing vector. Determination of DNA sequence was performed by dideoxy termination method using A. L. F. florescent auto DNA sequencer. The complete nucleotide sequence date of  $\alpha 2$  antigen gene was assigned in the GS-

DB, DDBJ, EMBL and NCBI nucleotide sequence databases with the following accession number D43841. (2) 200ml of LB medium were inoculated with over night culture of *E. Coli* carrying plasmid DNA which can express MBP-*M. leprae*  $\alpha$  antigen fusion protein. Cells were grown to mid log phase and the expression of MBP-*M. leprae*  $\alpha$  antigen fusion protein in the sonic extracts was absorbed to amylose resin followed by elution with 10mmol/L maltose. More than 10mg of fusion protein were obtained from the 200ml of culture. (3) The sensitivity of  $\alpha 2$ -ELISA and PGI-I-ELISA determined on the sera of L leprosy was 92% and 94%, respectively. The corresponding results for B and T leprosy patients were 58% and 68%, 38% and 30%, respectively.

Although *M. leprae* was the first identified bacterial pathogen of man, basically biochemical, immunological, diagnostic and therapeutic investigations have been severely limited because it remains one of the few human pathogens that have not been cultured in vitro. The construction of *M. leprae* recombinant DNA genomic library could provide a source of gene encoding proteins relevant for such studies, and the molecular cloning, expression of *M. leprae* DNA in a suitable host vector system offers a new way of obtaining large amount of well-characterized antigens. The results of this study suggested that the recombinant  $\alpha 2$  antigen could be used as a new specific antigen for sero-diagnosis of leprosy, especially the lepromatous leprosy.

\* Osaka Prefectural Institute for Public Health, Japan

\*\* National Sanatorium Haku-Komyouen, Japan



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Br  
Search PubMed for [ ] Go Clear  
Limits Preview/Index History Clipboard Details

About Entrez

Display Abstract Show: 20 Sort Send to Text

Text Version

1: Chin Med Sci J. 1999 Jun;14(2):102-6.

Related Articles, Links

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

## The relationship between expressions of N-myc and c-myc oncogenes in neuroblastoma: an in situ hybridization and immunocytochemical study.

Zhe X, Chen J, Liu T, Zhang L, Li P, Wang D.

Department of Pathology, Peking Union Medical College Hospital, National Laboratory of Medical Molecular Biology, CAMS & PUMC, Beijing 100730.

N-myc gene amplification is the most characteristic feature of neuroblastoma. c-myc oncogene, another member of myc gene family, plays an important role in cell proliferation and differentiation. Both of them may contribute to tumorigenesis of neuroblastoma. In this study we use the in situ hybridization and immunocytochemical methods to test the frequencies of N-myc and c-myc expressions in 20 cases of human neuroblastoma at mRNA and protein levels. The positive rates of the expression of N-myc are 90% and 100% detected by in situ hybridization and immunocytochemical methods respectively. The positive rates of c-myc are 80% and 85% respectively. Sixty percent of the 20 specimens tested by in situ hybridization and 55% by immunocytochemistry show an inverse relationship between the expressions of these two oncogenes and this may indicate that there are different gene expression controlling mechanisms in different cases.

PMID: 12901618 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act](#) | [Disclaimer](#)

Jun 7 2004 18:11:57